Orelabrutinib
Orelabrutinib is a drug for the treatment of cancer.
In China, it is approved for patients with mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, who have received at least one treatment in the past.
Orelabrutinib is an inhibitor of Bruton's tyrosine kinase.